New York State Common Retirement Fund Sells 1,093 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

New York State Common Retirement Fund trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.2% during the 4th quarter, Holdings Channel reports. The fund owned 19,828 shares of the company’s stock after selling 1,093 shares during the period. New York State Common Retirement Fund’s holdings in Medpace were worth $6,587,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MEDP. Kestra Investment Management LLC boosted its stake in shares of Medpace by 58.3% during the fourth quarter. Kestra Investment Management LLC now owns 1,105 shares of the company’s stock valued at $367,000 after purchasing an additional 407 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in Medpace by 602.0% during the fourth quarter. Venturi Wealth Management LLC now owns 344 shares of the company’s stock worth $114,000 after buying an additional 295 shares during the period. Truist Financial Corp boosted its position in Medpace by 166.2% during the 4th quarter. Truist Financial Corp now owns 10,277 shares of the company’s stock valued at $3,414,000 after acquiring an additional 6,417 shares in the last quarter. CIBC Asset Management Inc increased its holdings in shares of Medpace by 5.3% in the 4th quarter. CIBC Asset Management Inc now owns 936 shares of the company’s stock valued at $311,000 after acquiring an additional 47 shares during the period. Finally, Sanctuary Advisors LLC raised its position in shares of Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after acquiring an additional 844 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $339.48 on Thursday. Medpace Holdings, Inc. has a one year low of $302.01 and a one year high of $459.77. The stock has a market cap of $10.34 billion, a PE ratio of 26.88, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. The stock has a 50-day moving average of $343.04 and a two-hundred day moving average of $346.19.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.